Adjuvant durvalumab extends survival in small cell lung cancer
For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer ...
oncnursingnews3d
Lung Cancer Trial Falls Short of Goal, But Presents Clinical Benefit in Some Patients
While none of the experimental combinations met efficacy targets, durvalumab with monalizumab and ceralasertib showed ...
Medscape4d
'One of the Most Impactful' ESMO Studies: Durvalumab in Muscle-Invasive Bladder Cancer
BARCELONA — Adding the immune checkpoint inhibitor durvalumab to standard treatment for muscle-invasive bladder cancer (MIBC) ...
Targeted Oncology4d
Adaptive NSCLC Trial Misses Target Efficacy, Reaches Clinical Benefit in Some Patients
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...
Researchers announce clinical trial results for hard-to-treat breast and bladder cancers
Professors Tom Powles and Peter Schmid recently delivered results from their phase three clinical trials during Sunday's ...
Targeted Oncology4d
Tremelimumab Plus Durvalumab Turns Heads With Updated Five-Year Data in uHCC
The HIMALAYA study showed that the combination of tremelimumab and durvalumab significantly improved overall survival in ...
Cure Today5d
Imfinzi Continuously Demonstrates Survival Benefit in Limited Stage SCLC
Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with ...
Medpage Today on MSN5d
Win for Perioperative Durvalumab in Muscle-Invasive Bladder Cancer
Adding perioperative durvalumab (Imfinzi) to neoadjuvant chemotherapy significantly improved survival outcomes in ...
Becker's Hospital Review5d
Cancer drugs: 4 updates to know
AstraZeneca's bladder cancer drug durvalumab, called Imfinzi, reduced the risk of disease progression and recurrence by 32% and the risk of death by 25% in patients with bladder cancer in a global, ...
BioSpace5d
AstraZeneca’s Perioperative Imfinzi ‘Significantly Extends Survival’ in Type of Bladder Cancer
The readout comes from the Phase III NIAGARA study, which tested an investigational perioperative regimen of Imfinzi ...
Cancer Therapy Advisor5d
Will Durvalumab Transform Standard Care in MIBC?
Incorporating perioperative durvalumab into treatment with neoadjuvant chemotherapy and radical cystectomy prolongs EFS and OS in patients with MIBC.
AZN : IMFINZI Regimen Reduces Death Risk By 25% In Late-Stage Muscle-Invasive Bladder Cancer Trial
AstraZeneca Plc (AZN.L, AZN) announced that the NIAGARA Phase III trial showed its IMFINZI (durvalumab) in combination with ...